Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma

New England Journal of Medicine

Volumn 346, Issue 4, 2002, Pages 235-242

  Coiffier, Bertrand ^a,j   Lepage, Eric ^b   Brière, Josette ^c   Herbrecht, Raoul ^d   Tilly, Hervé ^e   Bouabdallah, Reda ^f   Morel, Pierre ^g   Van Den Neste, Eric ^h   Salles, Gilles ^a   Gaulard, Philippe ^b   Reyes, Felix ^b   Lederlin, Pierre ⁱ   Gisselbrecht, Christian ^c  

^a UNIVERSITÉ LYON 1   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e Centre Becquerel   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g Centre Hospitalier de LENS   (France)

^h UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GERIATRIC CARE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL TIME; TOXICITY; TREATMENT FAILURE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RECURRENCE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0037165261     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011795     Document Type: Article

References (29)

1. Non-Hodgkin's lymphomas
2. A predictive model for aggressive non-Hodgkin's lymphoma
3. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients
4. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
6. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
7. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience
8. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte study
9. What treatment for elderly patients with aggressive lymphoma?
10. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
11. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
12. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
13. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
14. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
15. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantlecell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
16. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
17. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
18. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
19. Good clinical practice for trials on medicinal products in the European community
20. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
21. A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: The LNH93-5 study
22. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival - A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years
23. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
24. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
25. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
26. CHOP versus MACOP-B in aggressive lymphoma - A Nordic Lymphoma Group randomised trial
27. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group